# Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT02598583** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- PNH

## Interventions

- **BIOLOGICAL:** ALXN1210

## Key facts

- **NCT ID:** NCT02598583
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-12
- **Primary completion:** 2016-07-14
- **Final completion:** 2021-03-11
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598583, "Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02598583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*